Τόμος 27 (2013) – Τεύχος 3 – Άρθρο 5- Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση – Volume 27 (2013) – Issue 3 – Article 5 – Review of Clinical Pharmacology and Pharmacokinetics-International Edition

By | | Άρθρο επισκόπησης - Review Article, Ιωάννης Τζουβελέκης - Ioannis Tzouvelekis, Κυριακή Αποστολίδου - Kyriaki Apostolidou, Κωνσταντίνος Καλούσης - Konstantinos Kalousis, Μαρία Μυρωνίδου-Τζουβελέκη - Maria Mironidou-Tzouveleki, Μάριος Σαββίδης- Marios Savvidis, Πλήρες Κείμενο στα Αγγλικά - Full Text in English, Σωτήρης Μητσόπουλος - Sotiris Mitsopoulos

 

Τίτλος – Title

Hallucinogenic Plant and Fungal Species Naturally Growing in Mediterranean Countries
Συγγραφέας – Author

Maria Mironidou-Tzouveleki, Marios Savvidis, Kyriaki Apostolidou, Sotiris Mitsopoulos, Ioannis Tzouvelekis, Konstantinos Kalousis
A’ Laboratory of Pharmacology, School of Medicine, Aristotle University, Thessaloniki, Hellas
Παραπομπή – Citation

Mironidou-Tzouveleki M., Savvidis M., Apostolidou K., Mitsopoulos S., Tzouvelekis I., Kalousis K.: Hallucinogenic Plant and Fungal Species Naturally Growing in Mediterranean Countries, Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 27: 131-1144 (2013)
Ημερομηνία Δημοσιευσης – Publication Date
31 Δεκεμβρίου 2013 – 2013-12-31
Γλώσσα Πλήρους Κειμένου –
Full Text Language

Αγγλικά – English
Λέξεις κλειδιά – Keywords
Μεσογειακές χώρες, παραισθησιογόνα φύτα, παραισθησιογόνοι μύκητες, Μανδραγόρας, Κάνναβις –
Mediterranean countries, hallucinogenic plant, hallucinogenic fungus, Phalaris aquatica, Mandragora officinarum, Atropa belladonna, Datura stramonium, Hyoscyamus niger, Cannabis sativa, Psilocybe semilanceata, Amanita muscaria
Λοιποί Όροι – Other Terms

Άρθρο Επισκόπησης –
Review Article
Περίληψη – Summary

 This review focuses on certain hallucinogenic plant and fungal species naturally growing in Mediterranean coast countries. The plants included in this review are Phalaris aquatica, Peganum harmala, Mandragora officinarum, Hyoscyamus niger, Atropa belladonna, Datura stramonium and Cannabis sativa. In addition, the fungal species Psilocybe semilanceata and Amanita muscaria are included. All of these species are known to be used as recreational drugs due to their hallucinogenic properties. We focus on the geographic distribution of these plants and fungi, the  hallucinogenic substances they contain, their pharmacological properties, the effects their consumption exerts on the human organism and the patterns of use (both deliberate and accidental). We conclude that the health care providers of these areas should be prepared to deal with cases of either deliberate or accidental intoxication. The states’ measures against deliberate use should vary per species due to differences in geographic distribution, prevalence and patterns of use.
Αναφορές – References
 1. Halpern J.H.: Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol. Ther. 102: 131-138 (2004)
2. Mironidou-Tzouveleki Μ. et al. (eds): Plants: magic, religion or only illusions? University Studio Press, Thessaloniki, Greece, 2010
3. United Nations Office on Drugs and Crime, World Drug Report 2012 (United Nations Publication, Sales No. E.12.XI.1)
4. Zhou L., Hopkins A.A., Huhman D.V., Sumner L.W.: Efficient and sensitive method for quantitative analysis of alkaloids in hardinggrass (Phalaris aquatica L.). J. Agric. Food Chem. 54: 9287-9291 (2006)
5. The Euro+Med Plantbase: Available from: http://ww2.bgbm.org/EuroPlusMed/PTaxonDetail.asp?NameCache=Phalaris%20aquatica&PTRefFk=7100000
6. Binder E.M., Blodgett D.J., Currin J.F., Caudell D., Cherney J.H., LeRoith T.: Phalaris arundinacea (reed canarygrass) grass staggers in beef cattle. J. Vet. Diagn. Invest. 22: 802-805 (2010)
7. Shen H.W., Jiang X.L., Winter J.C., Yu A.M.: Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, phar-macokinetics, drug interactions, and pharmacological actions. Curr. Drug Metab. 11: 659-666 (2010)
8. Skerritt J.H., Guihot S.L., McDonald S.E., Culvenor R.A.: Development of immunoassays for tyramine and tryptamine toxins of Phalaris aquatica L. J. Agric. Food Chem. 48: 27-32 (2000)
9. Frison G., Favretto D., Zancanaro F., Fazzin G., Ferrara S.D.: A case of beta-carboline alkaloid intoxication following ingestion of Peganum harmala seed extract.  Forensic. Sci. Int. 179: e37-e43 (2008)
10. Cakic V., Potkonyak J., Marshall A.: Dimethyltryptamine (DMT): subjective effects and patterns of use among Australian recreational users. Drug Alcohol Depend. 111(1-2): 30-37 (2010)
11. Santos R.G., Landeira-Fernandez J., Strassman R.J., Motta V., Cruz A.P.: Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J. Ethnopharmacol. 112 : 507-513 (2007)
12. Keiser M.J., Setola V., Irwin J.J., Laggner C., Abbas A.I., Hufeisen S.J., Jensen N.H., Kuijer M.B., Matos R.C., Tran T.B., Whaley R., Glennon R.A., Hert J., Thomas K.L., Edwards D.D., Shoichet B.K., Roth B.L.: Predicting new molecular targets for known drugs. Nature 462 (7270): 175-181 (2009)
13. Riba J., Anderer P., Jané F., Saletu B., Barbanoj M.J.: Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology 50(1): 89-101 (2004)
14. Ray T.S.: Psychedelics and the human receptorome. PLoS One. 5(2): e9019 (2010)
15. Dos Santos R.G., Grasa E., Valle M., Ballester M.R., Bouso J.C., Nomdedéu J.F., Homs R., Barbanoj M.J., Riba J.: Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology 219: 1039-1053 (2012)
16. Gable R.S.: Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction 102(1): 24-34 (2007)
17. Freedland C.S., Mansbach R.S.: Behavioral profile of constituents in ayahuasca, an Amazonian psychoactive plant mixture. Drug Alcohol Depend. 54: 183-194 (1999)
18. Ciprian-Ollivier J., Cetkovich-Bakmas M.G. Altered con-sciousness states and endogenous psychoses: a common molecular pathway? Schizophr. Res. 28(2-3): 257-265 (1997)
19. Takeda N., Ikeda R., Ohba K., Kondo M.: Bufotenine reconsidered as a diagnostic indicator of psychiatric disorders. Neuroreport 6: 2378-2380 (1995)
20. Krebs-Thomson K., Ruiz E.M., Masten V., Buell M., Geyer M.A.: The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology 189: 319-329 (2006)
21. Shen H.W., Jiang X.L., Yu A.M.: Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltrypta-mine and bufotenine, and application to pharmacokinetic study. Bioanalysis 1(1): 87-95 (2009)
22. Shen H.W., Wu C., Jiang X.L., Yu A.M.: Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. Biochem. Pharmacol. 80: 122-128 (2010)
23. Halberstadt A.L., Buell M.R., Masten V.L., Risbrough V.B., Geyer M.A.: Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. Psychopharmacology 201: 55-66 (2008)
24. Winter J.C., Amorosi D.J., Rice K.C., Cheng K., Yu A.M.: Stimulus control by 5-methoxy-N,N-dimethyl-tryptamine in wild-type and CYP2D6-humanized mice. Pharmacol Biochem Behav. 99: 311-315 (2011)
25. Shen H.W., Jiang X.L., Yu A.M.: Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice. Drug Metab. Dispos. 39: 1227-1234 (2011)
26. Emanuele E., Colombo R., Martinelli V., Brondino N., Marini M., Boso M., Barale F., Politi P.: Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia. Neuro. Endocrinol. Lett. 31: 117-121 (2010)
27. Liester M.B., Prickett J.I.: Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions. J. Psychoactive Drugs 44: 200-208 (2012)
28. Farouk L., Laroubi A., Aboufatima R., Benharref A., Chait A.: Evaluation of the analgesic effect of alkaloid extract of Peganum harmala L.: possible mechanisms involved. J. Ethnopharmacol. 115: 449-454 (2008)
29. Astulla A., Zaima K., Matsuno Y., Hirasawa Y., Ekasari W., Widyawaruyanti A., Zaini N.C., Morita H.: Alkaloids from the seeds of Peganum harmala showing antiplasmodial and vasorelaxant activities. J. Nat. Med. 62: 470-472 (2008)
30. The Euro+Med Plantbase: Available from: http://ww2.bgbm.org/EuroPlusMed/PTaxonDetail.asp?NameCache=Peganum%20harmala&PTRefFk=7400000
31. Yuruktumen A., Karaduman S., Bengi F., Fowler J.: Syrian rue tea: a recipe for disaster. Clin. Toxicol. 46: 749-752 (2008)
32. Herraiz T., González D., Ancín-Azpilicueta C., Arán V.J., Guillén H.: beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem. Toxicol. 48: 839-845 (2010)
33. Zhao T., He Y.Q., Wang J., Ding K.M., Wang C.H., Wang Z.T.: Inhibition of human cytochrome P450 enzymes 3A4 and 2D6 by β-carboline alkaloids, harmine derivatives. Phytother. Res. 25: 1671-1677 (2011)
34. Hemmateenejad B., Abbaspour A., Maghami H., Miri R., Panjehshahin M.R.: Partial least squares-based multivariate spectral calibration method for simultaneous determination of beta-carboline derivatives in Peganum harmala seed extracts.  Anal. Chim. Acta 575: 290-299 (2006)
35. Nasehi M., Sharifi S., Zarrindast M.R.: Involvement of the cholinergic system of CA1 on harmane-induced amnesia in the step-down passive avoidance test. J. Psychopharmacol. 26: 1151-1161 (2012)
36. Gutstein H.B., Akil H. (eds): Chapter 21: Opioid analgesics. In: (Brunton L.L., Lazo J.S., Parker K.L., eds):  Goodman & Gilman’s: The pharmacological basis of therapeutics. Pp. 547-590. 11th ed. The McGraw-Hill Companies, USA, 2006
37. Fernstrom J.D.: Effects and side effects associated with the non-nutritional use of tryptophan by humans. J. Nutr. 142: 2236S-2244S (2012)
38. Brown J.H., Taylor P. (eds): Chapter 7: Muscarinic receptor agonists and antagonists. In: (Brunton L.L., Lazo J.S., Parker K.L., eds):  Goodman & Gilman’s: The pharmacological basis of therapeutics. Pp. 183-200. 11th ed. USA. The McGraw-Hill Companies, USA, 2006
39. Lee M.R.: Solanaceae IV: Atropa belladonna, Deadly Nightshade. J. R. Coll. Physicians Edinb. 37: 77-84 (2007)
40. Oerther S., Behrman A.D., Ketcham S.: Herbal hallucinations: common abuse situations seen in the emergency department. J. Emerg. Nurs. 36: 594-596 (2010)
41. Spina S.P., Taddei A.: Teenagers with Jimson weed (Datura stramonium) poisoning. CJEM. 9: 467-468 (2007)
42. Bouziri A., Hamdi A., Borgi A., Hadj S.B., Fitouri Z., Menif K., Ben Jaballah N.: Datura stramonium L. poisoning in a geophagous child: a case report. Int. J. Emerg. Med. 4: 31 (2011)
43. Manning B.H. (eds): Anticholinergics. In: (Olson K.R., ed.): Poisoning & Drug Overdose. Pp. 85-87. 5th ed., The McGraw-Hill Companies, USA, 2007
44. Norton S. (ed.): Chapter 27: Toxic effects of plants. In: (Klaassen C.D., ed.):  Casarett & Doull’s Toxicology. Pp. 965-976. 6th ed., The McGraw-Hill Companies, USA, 2001
45. Linden C.H., Lorejoy F.H. Jr., eds): Chapter 391: Poisoning and drug overdosage. In: (Fauci A.S., Braunwald E., Isselbacher K.J., Wilson J.D., Martin J.b., Kasper D.L., Hauser S.L., Longo D.L., eds): Harrison’s Principles of Internal Medicine. Pp. 2523-2544, 14th ed. The McGraw-Hill Companies, USA, 1998
46. Kurzbaum A., Simsolo C., Kvasha L., Blum A.: Toxic delirium due to Datura stramonium. Isr. Med. Assoc. J. 3: 538-539 (2001)
47. Berdai M.A., Labib S., Chetouani K., Harandou M.: Atropa belladonna intoxication: a case report. Pan. Afr. Med. J. 11: 72 (2012)
48. Tsiligianni I.G., Vasilopoulos T.K., Papadokostakis P.K., Arseni G.K., Eleni A., Lionis C.D.: A two cases clinical report of mandragora poisoning in primary care in Crete, Greece: two case report. Cases J. 2: 9331 (2009)
49. Doneray H., Orbak Z., Karakelleoglu C.: Clinical outcomes in children with hyoscyamus niger intoxication not receiving physostigmine therapy. Eur. J. Emerg. Med. 14: 348-350 (2007)
50. Spoerke D.G., Hall A.H., Dodson C.D., Stermitz F.R., Swanson C.H. Jr, Rumack B.H.: Mystery root ingestion.  J. Emerg. Med. 5: 385-388 (1987)
51. Centers for Disease Control and Prevention (CDC). Jimsonweed poisoning associated with a homemade stew – Maryland, 2008. MMWR Morb Mortal Wkly Rep. 59 (4): 102-104 (2010)
52. The European Agency for the evaluation of Medicinal Products. Veterinary Medicines Evaluation Unit. Committee for veterinary medicinal products.: Atropa Belladonna. Summary report. (December 1998)
53. Hanus L.O., Rezanka T., Spízek J., Dembitsky V.M.: Substances isolated from Mandragora species. Phytochemistry 66: 2408-2417 (2005)
54. Piccillo G.A., Miele L., Mondati E., Moro P.A., Musco A., Forgione A., Gasbarrini G., Grieco A.: Anticholinergic syndrome due to ‘Devil’s herb’: when risks come from the ancient time. Int. J. Clin. Pract. 60: 492-494 (2006)
55. Zárate R., el Jaber-Vazdekis N., Medina B., Ravelo A.G.: Tailoring tropane alkaloid accumulation in transgenic hairy roots of Atropa baetica by over-expressing the gene encoding hyoscyamine 6-beta-hydroxylase. Biotechnol. Lett. 28: 1271-1277 (2006)
56. DeFrates L.J., Hoehns J.D., Sakornbut E.L., Glascock D.G., Tew A.R.: Antimuscarinic intoxication resulting from the ingestion of moonflower seeds. Ann. Pharmacother. 39: 173-176 (2005)
57. Mateus L., Cherkaoui S., Christen P., Veuthey J.L.: Capillary electrophoresis for the analysis of tropane alkaloids: pharmaceutical and phytochemical applications. J. Pharm. Biomed. Anal. 18: 815-825 (1998)
58. Lee M.R.: The Solanaceae II: The mandrake (Mandragora officinarum); in league with the Devil. J. R. Coll. Physicians Edinb. 36: 278-285 (2006)
59. Lee M.R.: Solanaceae III: henbane, hags and Hawley Harvey Crippen. J. R. Coll. Physicians Edinb. 36: 366-373 (2006)
60. Nikolaou P., Papoutsis I., Stefanidou M., Dona A., Maravelias C., Spiliopoulou C., Athanaselis S.: Accidental poisoning after ingestion of “aphrodisiac” berries: diagnosis by analytical toxicology. J. Emerg. Med. 42: 662-665 (2012)
61. The Euro+Med Plantbase: Available from: http://ww2.bgbm.org/EuroPlusMed/PTaxonDetail.asp?NameCache=Mandragora%20officinarum&PTRefFk=7100000
62. Vlachos P., Poulos L.: A case of mandrake poisoning. J. Toxicol. Clin. Toxicol. 19: 521-522 (1982)
63. The Euro+Med Plantbase: Available from: http://ww2.bgbm.org/EuroPlusMed/PTaxonDetail.asp?NameCache=Atropa%20bella-donna&PTRefFk=7100000
64. Joshi P., Wicks A.C., Munshi S.K.: Recurrent autumnal psychosis. Postgrad. Med. J. 79(930): 239-240 (2003)
65. Southgate H.J., Egerton M., Dauncey E.A.: Lessons to be learned: a case study approach. Unseasonal severe poisoning of two adults by deadly nightside (Atropa belladonna). J. R. Soc. Promot. Health 120: 127-130 (2000)
66. Caksen H., Odabaş D., Akbayram S., Cesur Y., Arslan S., Uner A., Oner A.F.: Deadly nightshade (Atropa belladonna) intoxication: an analysis of 49 children. Hum. Exp. Toxicol. 22: 665-668 (2003)
67. The Euro+Med Plantbase: Available from: http://ww2.bgbm.org/EuroPlusMed/PTaxonDetail.asp?NameCache=Datura%20stramonium&PTRefFk=7100000
68. Wiebe T.H., Sigurdson E.S., Katz L.Y.: Angel’s Trumpet (Datura stramonium) poisoning and delirium in adolescents in Winnipeg, Manitoba: Summer 2006. Paediatr. Child Health 13: 193-196. (2008)
69. Lazzarini D., Baffoni M.T., Cangiotti C., Di Fronzo G., Gerboni S., Micheli R., Morelli S., Morolli L., Ioli G.: Food poisoning by Datura stramonium: an unusual case report. Intern. Emerg. Med. 1(1): 88-90 (2006)
70. Vearrier D., Greenberg M.I.: Anticholinergic delirium following Datura stramonium ingestion: Implications for the Internet age. J. Emerg. Trauma Shock. 3(3): 303 (2010)
71. The Euro+Med Plantbase: Available from: http://ww2.bgbm.org/EuroPlusMed/PTaxonDetail.asp?NameCache=Hyoscyamus%20niger&PTRefFk=7100000
72. Orbak Z., Tan H., Karakelleoglou C., Alp H., Akdag R.: Hyoscyamus niger (henbane) poisonings in the rural area of East Turkey. MJAU 30: 145-148 (1998)
73. Begum S., Saxena B., Goyal M., Ranjan R., Joshi V.B., Rao Ch.V., Krishnamurthy S., Sahai M. Study of anti-inflammatory, analgesic and antipyretic activities of seeds of Hyoscyamus niger and isolation of a new coumarinolignan. Fitoterapia 81: 178-184 (2010)
74. Sengupta T., Vinayagam J., Nagashayana N., Gowda B., Jaisankar P., Mohanakumar K.P.: Antiparkinsonian effects of aqueous methanolic extract of Hyoscyamus niger seeds result from its monoamine oxidase inhibitory and hydroxyl radical scavenging potency. Neurochem. Res. 36: 177-186 (2011)
75. Sands J.M., Sands R.: Henbane chewing. Med. J. Aust. 2(2): 55-58 (1976)
76. Green B., Kavanagh D., Young R.: Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev. 22: 453-460 (2003)
77. The Euro+Med Plantbase: Available from: http://ww2.bgbm.org/EuroPlusMed/PTaxonDetail.asp?NameCache=Cannabis%20sativa&PTRefFk=7300000
78. Maykut M.O.: Health consequences of acute and chronic marihuana use. Prog. Neuropsychopharmacol. Biol. Psychiatry 9: 209-238 (1985)
79. Ashton C.H.: Adverse effects of cannabis and cannabinoids. Br. J. Anaesth. 83: 637-649 (1999)
80. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M.: Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 89: 309-380 (2009)
81. Battista N., Di Tommaso M., Bari M., Maccarrone M.: The endocannabinoid system: an overview. Front. Behav. Neurosci. 6: 9 (2012)
82. Grotenhermen F., Müller-Vahl K.: The therapeutic potential of cannabis and cannabinoids. Dtsch. Arztebl. Int. 109 (29-30): 495-501 (2012)
83. Kostoudi S., Koutousi C., Mironidou-Tzouveleki M.: Cannabinoids in clinical practice. Epitheor. Klin. Farmakol. Farmakokinet. 23: 265-272 (2005)
84. Passos I., Mironidou-Tzouveleki M.: Cannabinoids: Therapeutic potential against cocaine dependence. Epitheor. Klin. Farmakol. Farmakokinet. 29: 7-14 (2011)
85. Hall W., Degenhardt L.: Adverse health effects of non-medical cannabis use. Lancet 374(9698): 1383-1391 (2009)
86. Boros CA, Parsons DW, Zoanetti GD, Ketteridge D, Kennedy D. Cannabis cookies: a cause of coma. J. Paediatr. Child Health 32: 194-195 (1996)
87. Hall W., Degenhardt L.: Prevalence and correlates of cannabis use in developed and developing countries. Curr. Opin. Psychiatry 20: 393-397 (2007)
88. Appelboam A., Oades P.J.: Coma due to cannabis toxicity in an infant. Eur. J. Emerg. Med. 13: 177-179 (2006)
89. Amirav I., Luder A., Viner Y., Finkel M.: Decriminalization of cannabis-potential risks for children? Acta Paediatr. 100: 618-619 (2011)
90. Kalant H.: Adverse effects of cannabis on health: an update of the literature since 1996. Prog. Neuropsychopharmacol. Biol. Psychiatry 28: 849-863 (2004)
91. Johns A.: Psychiatric effects of cannabis. Br. J. Psychiatry 178: 116-122 (2001)
92. Crane N.A., Schuster R.M., Fusar-Poli P., Gonzalez R.: Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol. Rev. 23: 117-137 (2013)
93. Ramaekers J.G., Berghaus G., van Laar M,. Drummer O.H.: Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend. 73: 109-119 (2004)
94. Laumon B., Gadegbeku B., Martin J.L., Biecheler M.B.; SAM Group.: Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ 331: 1371 (2005)
95. Hall W., MacPhee D.: Cannabis use and cancer. Addiction 97: 243-247 (2002)
96. Zhang Z.F., Morgenstern H., Spitz M.R., Tashkin D.P., Yu G.P., Marshall J.R., Hsu T.C., Schantz S.P.: Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol. Biomarkers Prev. 8: 1071-1078 (1999)
97. Mehra R., Moore B.A., Crothers K., Tetrault J., Fiellin D.A.: The association between marijuana smoking and lung cancer: a systematic review. Arch. Intern. Med. 166: 1359-1367 (2006)
98. Moir D., Rickert W.S., Levasseur G., Larose Y., Maer-tens R., White P., Desjardins S.: A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem. Res. Toxicol. 21: 494-502 (2008)
99. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G.: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370 (9584): 319-328 (2007)
100. Hambrecht M., Häfner H.: Substance abuse and the onset of schizophrenia. Biol. Psychiatry 40: 1155-1163 (1996)
101. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., Verdoux H.: Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 156: 319-327 (2002)
102. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., van Os J.: Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 330: 11 (2005)
103. Degenhardt L., Hall W., Lynskey M.: Exploring the association between cannabis use and depression. Addiction 98: 1493-1504 (2003)
104. Beautrais A.L., Joyce P.R., Mulder R.T.: Cannabis abuse and serious suicide attempts. Addiction 94: 1155-1164 (1999)
105. Budney A.J., Hughes J.R.: The cannabis withdrawal syndrome. Curr. Opin. Psychiatry 19: 233-238 (2006)
106. Agrawal A., Lynskey M.T.: The genetic epidemiology of cannabis use, abuse and dependence. Addiction 101: 801-812 (2006)
107. Lassen J.F., Ravn H.B., Lassen S.F.: Hallucinogenic psilocybine containing mushrooms. Toxins contained in Danish wild mushrooms. Ugeskr. Laeger. 152: 314-317 (1990) [Article in Danish]
108. Adamczyk A, Sadakierska-Chudy A., Janoszka J., Rymkiewicz A., Dobosz T.: Hallucinogenic fungi (psilocybe). Part II. Identification of Psilocybe semilanceata by PCR.  Arch. Med. Sadowej. Kryminol. 57: 285-258 (2007) [Article in Polish]
109. Guzman G., Allen J.W., Gartz, J.: A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion. Annali di Museo Civico di Rovereto 14: 189-280 (1998)
110. Kovacic P., Somanathan R.: Novel, unifying mechanism for mescaline in the central nervous system: electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships. Oxid. Med. Cell Longev. 2: 181-190 (2009)
111. Beck O., Helander A., Karlson-Stiber C., Stephansson N.: Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions. J. Anal. Toxicol. 22: 45-49 (1998)
112. Vollenweider F.X., Geyer M.A.: A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res. Bull. 56: 495-507 (2001)
113. Satora L., Goszcz H., Ciszowski K.: Poisonings resulting from the ingestion of magic mushrooms in Kraków. Przegl Lek. 62: 394-396 (2005)
114. Marciniak B., Ferenc T., Kusowska J., Ciećwierz J., Kowalczyk E.: Poisoning with selected mushrooms with neurotropic and hallucinogenic effect. Med. Pr. 61: 583-595 (2010) [Article in Polish]
115. Peden N.R., Pringle S.D., Crooks J.: The problem of psilocybin mushroom abuse. Hum. Toxicol. 1: 417-424 (1982)
116. Hyde C., Glancy G., Omerod P., Hall D., Taylor G.S.: Abuse of indigenous psilocybin mushrooms: a new fashion and some psychiatric complications. Br. J. Psychiatry 132: 602-604 (1978)
117. van Amsterdam J., Opperhuizen A., van den Brink W.: Harm potential of magic mushroom use: a review. Regul. Toxicol. Pharmacol. 59: 423-429 (2011)
118. Michelot D., Melendez-Howell L.M.: Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycol. Res. 107: 131-146 (2003)
119. Li C., Oberlies N.H.: The most widely recognized mushroom: chemistry of the genus Amanita. Life Sci. 78: 532-538 (2005)
120. Tsujikawa K., Mohri H., Kuwayama K., Miyaguchi H., Iwata Y., Gohda A., Fukushima S., Inoue H., Kishi T.: Analysis of hallucinogenic constituents in Amanita mushrooms circulated in Japan. Forensic. Sci. Int. 164: 172-178 (2006)
121. Scotti de Carolis A., Lipparini F., Longo V.G.: Neuropharmacological investigations on muscimol, a psychotropic drug extracted from Amanita muscaria. Psychopharmacologia 15: 186-195 (1969)
122. Krogsgaard-Larsen P., Brehm L., Schaumburg K.: Muscimol, a psychoactive constituent of Amanita muscaria, as a medicinal chemical model structure. Acta Chem. Scand. B. 35: 311-324 (1981)
123. Brvar M., Mozina M., Bunc M.: Prolonged psychosis after Amanita muscaria ingestion. Wien. Klin. Wochenschr. 118(9-10): 294-297 (2006)
124. Chilton W.S., Ott J.: Toxic metabolites of Amanita pantherina, A. cothurnata, A. muscaria and other Amanita species. Lloydia 39(2-3): 150-157 (1976)
125. Tupalska-Wilczyńska K., Ignatowicz R., Poziemski A., Wójcik H., Wilczyński G.: Poisoning with spotted and red mushrooms-pathogenesis, symptoms, treatment. Wiad. Lek. 49(1-6): 66-71 1996 [article in Polish]
126. Benjamin D.R.: Mushroom poisoning in infants and children: the Amanita pantherina/muscaria group. J. Toxicol. Clin. Toxicol. 30(1): 13-22 (1992)
127. Satora L., Pach D., Butryn B., Hydzik P., Balicka-Slusarczyk B.: Fly agaric (Amanita muscaria) poisoning, case report and review. Toxicon. 45: 941-943 (2005)

Online ISSN 1011-6583

Bookmark the permalink.

Comments are closed.